Novo Nordisk will expand its manufacturing facility in USA

| By | API, Drug Manufacturing, Novo Nordisk

Denmark-based Novo Nordisk, the world’s leading diabetes care company, will embark on a $65 million expansion of its diabetes product manufacturing center at its campus in North Carolina, USA.

The pharmaceutical company currently employs over 1,000 manufacturing workers in Johnston County, North Carolina. The company expects to hire almost two dozen additional employees to staff as it expands its Diabetes Finished Products Facility. The Center is responsible for the formulation, filling, inspection, assembly and packaging of diabetes and obesity medicines.

The expansion comes less than two years after the company broke ground on a $2 billion facility nearby that will produce Diabetes Active Pharmaceutical Ingredients (DAPI) for a range of current and future type 2 diabetes medications and insulins. That facility will employ an additional 700 bio-manufacturing workers.

The company’s $2 billion DAPI facility, announced in August 2015 and believed to be North Carolina’s largest-ever industrial investment, is on track to be complete by 2021.

SOURCE: area development
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.